(Total Views: 506)
Posted On: 11/07/2021 7:34:27 PM
Post# of 153820
smurph,
You posted that you could not find Pfizer's Paxlovid trial at clinical trials.gov.
I believe this is it:
https://clinicaltrials.gov/ct2/show/study/NCT...amp;rank=1
This does not address your questions about side effects, but here is their exclusion criteria:
History of or need for hospitalization for the medical treatment of COVID-19
Prior to current disease episode, any confirmed SARS-CoV-2 infection
Known medical history of active liver disease
Receiving dialysis or have known moderate to severe renal impairment
Known human immunodeficiency virus (HIV) infection with a viral load greater than 400 copies/mL or taking prohibited medications for HIV treatment
Suspected or confirmed concurrent active systemic infection other than COVID-19
History of hypersensitivity or other contraindication to any of the components of the study intervention
Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4
Has received or is expected to receive convalescent COVID-19 plasma
Has received or is expected to receive any dose of a SARS-CoV-2 vaccine before the Day 34 visit
Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19 through the long-term follow-up visit
Known prior participation in this trial or other trial involving PF-07321332
Oxygen saturation of <92% on room air, or on their standard home oxygen supplementation for those who regularly receive chronic supplementary oxygen for an underlying lung condition
Females who are pregnant or breastfeeding
You posted that you could not find Pfizer's Paxlovid trial at clinical trials.gov.
I believe this is it:
https://clinicaltrials.gov/ct2/show/study/NCT...amp;rank=1
This does not address your questions about side effects, but here is their exclusion criteria:
History of or need for hospitalization for the medical treatment of COVID-19
Prior to current disease episode, any confirmed SARS-CoV-2 infection
Known medical history of active liver disease
Receiving dialysis or have known moderate to severe renal impairment
Known human immunodeficiency virus (HIV) infection with a viral load greater than 400 copies/mL or taking prohibited medications for HIV treatment
Suspected or confirmed concurrent active systemic infection other than COVID-19
History of hypersensitivity or other contraindication to any of the components of the study intervention
Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance or are strong inducers of CYP3A4
Has received or is expected to receive convalescent COVID-19 plasma
Has received or is expected to receive any dose of a SARS-CoV-2 vaccine before the Day 34 visit
Participating in another interventional clinical study with an investigational compound or device, including those for COVID-19 through the long-term follow-up visit
Known prior participation in this trial or other trial involving PF-07321332
Oxygen saturation of <92% on room air, or on their standard home oxygen supplementation for those who regularly receive chronic supplementary oxygen for an underlying lung condition
Females who are pregnant or breastfeeding
(3)
(0)
